Skip to main content

allogeneic cd19-specific universal car19-expressing t-lymphocytes

Generic: Allogeneic CD19-specific Universal CAR19-expressing T-lymphocytes

allogeneic cd19-specific universal car19-expressing t-lymphocytes: 1 clinical trial tracked.

allogeneic cd19-specific universal car19-expressing t-lymphocytes evidence translation

What we can confirm

1 tracked trial

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about allogeneic cd19-specific universal car19-expressing t-lymphocytes, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence0 indications · 1 study sponsors

Related indications

No linked indication is available.

Clinical Trial Registry Records (1)

A Single-Arm, Open-Label, Phase 1 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501, an Anti-CD19 Allogeneic CAR T Cell Therapy, And ALLO-647, An Anti-CD52 Monoclonal Antibody, in Patients With Relapsed/Refractory Large B-Cell Lymphoma or Follicular Lymphoma

NCT03939026Registry updated 2026-03-02·Phase 1·ALLO
Completed

Primary endpoint: Proportion of subjects experiencing Dose Limiting Toxicities at increasing doses of ALLO-501

Interventionalopen50 enrolledStarted 2019-05Completion 2025-017 sites · United StatesAllogene Therapeutics